Rafik Fellague-Chebra

Rafik Fellague-Chebra

Executive Global Group medical Director, Solid tumors franchise, GI cancers Novartis

Dr. Rafik Fellague-Chebra is an oncology leader with over 20 years of experience in clinical practice, research, and pharmaceutical development, combining expertise in medicine and biostatistics. He has held executive positions at major pharmaceutical companies including Novartis Oncology as Executive Global Group Medical Director, where he led initiatives in hematological and gastrointestinal malignancies, Pfizer where he directed the successful launch of Sutent for renal and neuroendocrine tumors, and GSK where he developed cancer vaccine programs. His current research investigates the intersection of AI, cancer biology and the human microbiome, focusing on how oncobiome modulation can overcome treatment resistance and enhance therapeutic efficacy. Dr. Fellague-Chebra views this work as representing the next paradigm shift in precision oncology.

1. Conference Day, 02. September 2025

9:20 Opening-Keynote: Digital twins: Enabling precision oncology 2.0

-From precision oncology to precision oncology 2.0: How AI and multi-omics integration are redefining individualized care strategies.

-The role of digital twins: Using virtual patient models to simulate disease progression, treatment responses, and predict outcomes.

-Use case in clinical development: Accelerating trial design, patient recruitment, and adaptive protocol optimization through predictive analytics.

-Regulatory and ethical considerations: What needs to be addressed for digital twin models and AI to be clinically validated and adopted.

9:50 Panel: Digitalization and AI in Clinical Trials

-Opportunities and Challenges – How are digital technologies and AI changing the efficiency, quality, and ethics of clinical trials?

-Automation and Data Analytics – What role does AI play in patient recruitment, data analysis, and decision-making?

-Future Perspectives – How can regulatory frameworks and technological innovations further advance the development of clinical trials?

-Human vs. Machine – How does the human factor remain relevant and crucial in an increasingly AI-driven research environment?

Check out the incredible speaker line-up to see who will be joining Rafik.

Download The Latest Agenda

In Partnership With:

Pharma IQ

Connect With Us

Questions?

Tel: +49 30 52001534

E-mail: eq@iqpc.de

Iqpc Icon

©2025 IQPC. All rights reserved.

Imprint:
Company information according to § 5 Telemediengesetz
IQPC Gesellschaft für Management Konferenzen mbH
Address: Rosenstrasse 2, 10178 Berlin, Germany
Tel: 49 30 52 001 534
E-mail: info@iqpc.de
Registered at: Amtsgericht Charlottenburg, HRB 76720
VAT-Number: DE210454451
Management: Torben Haagh, Richard A. Worden, Michael R. Worden

Impressum:
Firmeninformationen entsprechend § 5 Telemediengesetz
IQPC Gesellschaft für Management Konferenzen mbH
Adresse: Rosenstrasse 2, 10178 Berlin, Germany
Telefonnummer: 030 52001534
Email Adresse: info@iqpc.de
Registereintragungen: Amtsgericht Charlottenburg HRB 76720
Umsatzsteuer- Indentifikationsnummer DE210454451
Geschäftsführung: Torben Haagh, Richard A. Worden, Michael R. Worden